Latest Articles
Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress - The Manila Times
Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress The Manila Times
Published: Nov. 10, 2025, 2:19 a.m.
ASCENT-Gyn-01 Trial of Sacituzumab Govitecan Aims to Validate Clinical Utility of TROP2 ADCs in Pretreated Endometrial Cancer - OncLive
ASCENT-Gyn-01 Trial of Sacituzumab Govitecan Aims to Validate Clinical Utility of TROP2 ADCs in Pretreated Endometrial Cancer OncLive
Published: Sept. 26, 2025, 7:40 p.m.
Link copied to clipboard!